Sarcoidosis is characterized by multisystemic granulomatous lesions of unknownetiology. A 62-year-old womandeveloped sarcoidosis after treatment with oc-2a interferon (IFN) for 24 weeks (total dose: 522 million units) for chronic hepatitis C. She developed complete atrioventricular block and multiple noncaseating granulomatous lesions in the lung. IFN therapy, which may disturb cellular immuneactivation in some patients, may have contributed to the onset and progression of sarcoidosis.
Introduction
Sarcoidosis is a multisystemic granulomatous disorder. The mechanismof granuloma formation in sarcoidosis remains unclear, but the activation of lymphocytes and macrophages releasing potent mediators such as interleukin-2 and interferon (IFN)-y, which recruit, activate and proliferate these cells, is thought to play a role in the etiology of sarcoidosis (1) (2) (3) (4) (5) . IFN, which is atpresent widely used as an effective treatment for chronic hepatitis C (6), has several other effects including perturbation of the functions ofT lymphocytes and macrophages (7-ll) .
It might, therefore, contribute to the onset or the progression of sarcoidosis in some patients. Wedescribe a case of sarcoidosis after IFN therapy for chronic hepatitis C.
Case Report
A 62-year-old womanwith chronic hepatitis C was admitted to our hospital in January 1993 for IFN therapy. She had a medical history ofhypertension and cholelithiasis. Prior to IFN therapy, the chest X-ray film (Fig. 1A ) and the electrocardiogram (ECG) showed no abnormal findings. Liver biopsy revealed chronic active hepatitis 2a. Beginning on January 10, 1993, she received daily intramuscular injections of 9 million units of a-2a IFN for the first 2 weeks and then 6 million units 3 times per week. In April 1993, she began to experience general fatigue on exertion but continued to receive IFN until June 25. Serum alanine aminotransferase (ALT), which was 56 IU// prior to IFN therapy returned to normal range within 2 weeks after the initiation of IFN therapy, but increased again after the end of therapy. The feeling of general fatigue gradually increased after IFN therapy. Holter monitor, which was performed because bradycardia was recognized on auscultation revealed first degree atrioventricular (A-V) block on September 30 ( Fig. 2A) andcomplete A-V block on November 1 (Fig. 2B) . A dual-chamber pacemaker was permanently implanted on November 4, 1 993. The feeling of general fatigue subsequently disappeared, and the chest X-ray film showed no abnormal shadows at that time.
In June 1994, reticulo-nodular shadows were recognized in the middle and lower fields of the right lung on a routine chest X-ray film. The reticulo-nodular shadows did not disappear with time and thus, she was re-admitted for detailed examination of the abnormal lung shadows on September 6 (Fig. 3) , at which time she had no symptoms of pulmonary disease. On admission, her body temperature was 36. 1°C, heart rate 83/min and regular, and blood pressure was 152/98 mmHg.Physical examination of her heart and chest revealed no abnormalities. Nosignificant abnormality was noted on examination of the skin and no palpable lymph nodes were detected. The results of hematological examinations were within normal limits. Aspartate aminotransferase (AST) was 19 IU// and ALT was 8 IU//. Immunological examination revealed normal C-reactive protein. Angiotensin converting enzyme(ACE) was elevated to S arcoidosis after Interferon Therapy (Fig. 5A) . Severe fibrosis of the lung parenchyma was also noted in the subpleural area. The granulomas were composed of tightly clustered epithelioid histiocytes and, occasionally, multinucleated giant cells. Typical asteroid bodies were also noted in the giant cells (Fig. 5B) . Given the findings of elevated serum levels of ACEand lysozyme, con fluent patchy shadows on the chest X-ray film Figure 5 . Microphotographs of lung tissue obtained by thoracoscopic lung biopsy. A) Multiple non-necrotizing granulomatous inflammatory lesions involving the lung parenchyma and peribronchiolar area was observed (HE stain, xlOO). B) A typical asteroid body was also recognized in a non-necrotizing granuloma (HE stain, x400).
and lung CT, A-V block and histopathological findings, a diagnosis of sarcoidosis was made. The patient was started on 30 mg/day prednisolone daily on October 31. The patient's clinical signs including serum ACEand lysozyme levels, the con fluent patchy shadows on chest X-ray and the A-V block on ECGimproved. The lymphocytosis stimulating test with a-2a IFN and the proliferative responses of lymphocytes to phytohemagglutinin and concanavalin A were within the normal range.
Discussion
Sarcoidosis is a multisystemic granulomatous disorder of unknown etiology that most commonlyaffects young adults. Histopathologically, it is characterized by accumulation of T lymphocytes and mononuclear phagocytes that form noncaseating epithelioid granulomas and derangement of the normal tissue architecture in affected organs (1) . Although the precise pathogenesis of sarcoidosis remains unclear, the granuloma formation which occurs in affected patients is thought to be a consequenceof exaggerated cellular immuneresponses to a variety of exogenous antigens or self-antigens (1) (2) (3) (4) (5) . It is well documented that interleukins 1 and 2 and IFN-yplay roles in granulation, but a variety of other cytokines might also either directly or indirectly affect the release and function of the cytokine network.
IFN-oc is widely employed for the treatment of chronic active hepatitis C because of its anti-viral effects (6). However, it also exerts a variety of other immunological effects, including the inhibition of macrophages functions and interference with IL-2 production by T-lymphocytes (7-1 1). In addition, many types of immunological disorders including thyroid disease and pneumonitis have been reported as side effects of IFN therapy (12, 13 ).
In the case described here, general fatigue, A-V block and abnormal shadows on chest X-ray films were recognized 3 months, 8 months and 17 months after the administration of IFN, respectively. General fatigue is one of the most prominent adverse effects ofIFN therapy and is usually recognized as early as within 2 weeks of treatment (14) . The present patient complained of general fatigue which occurred as late as 3 months after the initiation of IFN therapy and might have been due to A-Vblock and/or sarcoidosis itself. In sarcoidosis, heart diseases including sudden death sometimes precede other symptomsand complete A-Vblock occurs in as many as 5 1%of patients with cardiac sarcoidosis (15, 16) . In addition to the above findings, because A-Vblock as well as other symptomsimproved with steroid therapy in the present patient, it is reasonable to assume that the A-Vblock was due to sarcoidosis. In this case, the abnormal shadows on chest Xray films appeared 17 months after IFN therapy began and the final diagnosis of sarcoidosis was made by histologic, clinical, and radiograpic findings. However,webelieve that general fatigue and A-V block, as symptoms of sarcoidosis, preceded other characteristic symptomsof this disease. Ohhata et al (17) reported a case, in which subcutaneous S arcoidosis after Interferon Therapy sarcoid nodules developed 2 months after the start of IFN therapy for type C chronic active hepatitis complicated with pre-existing sarcoidosis and improved after the cessation of IFN therapy. This report suggests that exogenous IFN contributes to the development of sarcoidosis in someway yet to be elucidated. Our patient had no past medical history of sarcoidosis and there were no signs of sarcoidosis before IFN therapy on physical examination, ECG, chest X-ray film or liver biopsy. Thus, it seems probable that sarcoidosis developed after the patient was started on IFN therapy. It might take a long time from the activation of cellular immunologic reactions by exogenousIFN to the formation of sarcoid granulomas or the damage of the tissues to appear. Abdi et al (18) reported a case in which sarcoidosis developed 8 months after the initiation of IFN therapy. The autoimmune diseases induced by IFN therapy do not always improve after the cessation of IFN and persist for months (19, 20) . Therefore, it is considered that the immune system, once it has been activated by exogenous IFN, might sometimes develop automatically without the stimulation of exogenousIFN. Becausethe symptomsof sarcoidosis were recognized after the termination of IFN therapy in our patient, it is possible to think that cellular immunologic reactions sometimes start to develop during IFN therapy and become prominent after the end of IFN therapy. Consequently, it is necessary to carefully monitor patients for abnormal immunological reactions not only during but also following IFN therapy.
